9 results about "Antibiotic Agents" patented technology

Compounds and methods for combinatorial drug discovery in nanoliter droplets are described herein. More particularly, novel synergistic agents that increase efficacy of antibiotic agents to treat bacterial infections are described.

The application discloses a preparation method and application of a novel nano-antibiotic agent for preventing and treating tobacco bacterial wilt, and belongs to the technical field of tobacco bacterial wilt prevention and treatment. Under the catalysis of N, N'-dicyclohexyl carbodiimide and 4-dimethylaminopyridine, daphnetin is condensed with carboxymethyl chitosan to form nanoparticles, and the prepared novel nanoparticles have high water solubility and good prevention and treatment effect.

An orally administrable composition for maintaining oral health comprising as active ingredients an antibiotic agent, an anti-inflammatory agent and optionally a remineralizing agent is disclosed. Methods of using the composition for maintaining or improving oral health and for treating oral diseases or conditions by self-administration or by administration by a health care professional are also provided.

The present disclosure relates to a conjugated prodrug comprising a peptide conjugated to an antibiotic molecules via a cleavable linker and pharmaceutical compositions thereof. Also disclosed are methods of enhancing the intracellular concentration of an antibiotic agent in a bacterium and methods of treating a patient for a bacterial infection.

This disclosure relates to the crystalline hydrate forms of (S)-2-((R)-6-(N-((1s,3S)-3-amino-cyclobutyl)carbamimidoyl)chroman-2-yl)-2-((((Z)-1-(2-aminothiazol-4-yl)-2-(((S)-2,2-dimethyl-4-oxo-1-(sulfooxy)azetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)propanoic acid, including crystalline hydrate form A, crystalline hydrate form B and crystalline hydrate form D, which are useful as antibiotic agents for the treatment of bacterial infections, such as bacterial infections caused by gram-negative bacteria, including strains that are multidrug resistant.

This disclosure relates to pentagalloyl glucose compositions and uses in managing microbial infections and compositions related thereto. In certain embodiments, this disclosure relates to compositions of pentagalloyl glucose. In certain embodiments, this disclosure relates to methods of treating or preventing a microbial infection, e.g., an antimicrobial resistant microbial infection, comprising administering to a subject in need thereof an effective amount of pentagalloyl glucose or salt thereof. In certain embodiments, the microbe is bacteria or fungi resistant to one or more antibiotic agents or antifungal agents.

Abstract Radiolabelled liposomes are provided for treating cancer. The radiolabelled liposomes comprise of a radionuclide such as 99mTc, 186Re, 188Re, or a combination thereof. The liposome may comprise a nanoliposome, a lipid, a phospholipid, cholesterol or a cholesterol analogue, and may further comprise a drug, chemotherapeutic agent, antibiotic agent or treatment molecule. In an embodiment, radiolabelled liposomes comprising (186Re) obisbemeda are administered to the patients. The radiolabelled liposomes may be administered as an infusate by intraventricular administration, including through an Ommaya reservoir, or by convection-enhanced delivery using one or more catheters. The therapies may further include imaging the radiolabelled liposome during or after administration. Abstract

Provided herein are methods for preventing or treating an infection caused by a Nontuberculous mycobacterium (NTM) species in a subject comprising administering to the subject an effective amount of an antibody or an antigen-binding fragment thereof that binds to a tip region of a DNABII peptide. Also provided in are methods for sensitizing a biofilm to an antibiotic agent, wherein the biofilm comprises a Nontuberculous mycobacterium (NTM) species, the method comprising contacting the biofilm with an antibody or an antigen-binding fragment thereof that binds to a tip region of a DNABII peptide.

The invention discloses an ophthalmic gel preparation and a preparation method thereof, and belongs to the field of ophthalmic administration. The preparation is prepared from the following components in percentage by mass: 13 to 26 percent of temperature-sensitive gelling polymer, 0.05 to 0.30 percent of ion-sensitive gelling polysaccharide, 0.02 to 0.20 percent of aldehyde polysaccharide, 0.05 to 0.50 percent of amino polymer, 0.01 to 2.00 percent of buffer system, 0.10 to 2.00 percent of isoosmotic adjusting agent and the balance of water, and the aldehyde polysaccharide and the amino polymer form an imine bond dynamic cross-linked network. The preparation method comprises the steps of low-temperature dissolution, mixing, pH adjustment, sterilization and filling. The preparation is good in flowability when being dropped, can be quickly gelatinized and self-recovered under the action of temperature and tear ions after entering eyes, improves the controllability of ocular surface retention and drug release, and can be used for packaging without bacteriostatic agents.